These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 29857160)

  • 1. Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation.
    Wuriyanghai Y; Makiyama T; Sasaki K; Kamakura T; Yamamoto Y; Hayano M; Harita T; Nishiuchi S; Chen J; Kohjitani H; Hirose S; Yokoi F; Gao J; Chonabayashi K; Watanabe K; Ohno S; Yoshida Y; Kimura T; Horie M
    Heart Rhythm; 2018 Oct; 15(10):1566-1574. PubMed ID: 29857160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Ma D; Wei H; Lu J; Huang D; Liu Z; Loh LJ; Islam O; Liew R; Shim W; Cook SA
    Stem Cell Res Ther; 2015 Mar; 6(1):39. PubMed ID: 25889101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studying KCNQ1 Mutation and Drug Response in Type 1 Long QT Syndrome Using Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Wei H; Wu J; Liu Z
    Methods Mol Biol; 2018; 1684():7-28. PubMed ID: 29058180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis.
    Ronchi C; Bernardi J; Mura M; Stefanello M; Badone B; Rocchetti M; Crotti L; Brink P; Schwartz PJ; Gnecchi M; Zaza A
    Cardiovasc Res; 2021 Jan; 117(2):472-483. PubMed ID: 32061134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation.
    Mura M; Lee YK; Pisano F; Ginevrino M; Boni M; Calabrò F; Crotti L; Valente EM; Schwartz PJ; Tse HF; Gnecchi M
    Stem Cell Res; 2019 May; 37():101437. PubMed ID: 31009818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression-Replacement
    Dotzler SM; Kim CSJ; Gendron WAC; Zhou W; Ye D; Bos JM; Tester DJ; Barry MA; Ackerman MJ
    Circulation; 2021 Apr; 143(14):1411-1425. PubMed ID: 33504163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation.
    Mura M; Lee YK; Pisano F; Ginevrino M; Boni M; Calabrò F; Crotti L; Valente EM; Schwartz PJ; Tse HF; Gnecchi M
    Stem Cell Res; 2019 May; 37():101431. PubMed ID: 30974404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-Scale Simulation of the Phenotypical Variability Induced by Loss-of-Function Long QT Mutations in Human Induced Pluripotent Stem Cell Cardiomyocytes.
    Paci M; Casini S; Bellin M; Hyttinen J; Severi S
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-specific induced pluripotent stem-cell models for long-QT syndrome.
    Moretti A; Bellin M; Welling A; Jung CB; Lam JT; Bott-Flügel L; Dorn T; Goedel A; Höhnke C; Hofmann F; Seyfarth M; Sinnecker D; Schömig A; Laugwitz KL
    N Engl J Med; 2010 Oct; 363(15):1397-409. PubMed ID: 20660394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
    Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microscopic mechanisms for long QT syndrome type 1 revealed by single-channel analysis of I(Ks) with S3 domain mutations in KCNQ1.
    Eldstrom J; Wang Z; Werry D; Wong N; Fedida D
    Heart Rhythm; 2015 Feb; 12(2):386-94. PubMed ID: 25444851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2.
    Giannetti F; Barbieri M; Shiti A; Casini S; Sager PT; Das S; Pradhananga S; Srinivasan D; Nimani S; Alerni N; Louradour J; Mura M; Gnecchi M; Brink P; Zehender M; Koren G; Zaza A; Crotti L; Wilde AAM; Schwartz PJ; Remme CA; Gepstein L; Sala L; Odening KE
    Europace; 2023 May; 25(5):. PubMed ID: 37099628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the I
    Zhong L; Yan Z; Jiang D; Weng KC; Ouyang Y; Zhang H; Lin X; Xiao C; Yang H; Yao J; Kang X; Wang C; Huang C; Shen B; Chung SK; Jiang ZH; Zhu W; Neher E; Silva JR; Hou P
    Circ Res; 2024 Sep; 135(7):722-738. PubMed ID: 39166328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of eight human induced pluripotent stem cell (iPSC) lines from familial Long QT Syndrome type 1 (LQT1) patients carrying KCNQ1 c.1697C>A mutation (NUIGi005-A, NUIGi005-B, NUIGi005-C, NUIGi006-A, NUIGi006-B, NUIGi006-C, NUIGi007-A, and NUIGi007-B).
    Ge N; Liu M; Krawczyk J; McInerney V; Galvin J; Shen S; O'Brien T; Prendiville T
    Stem Cell Res; 2019 Aug; 39():101502. PubMed ID: 31415974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease characterization using LQTS-specific induced pluripotent stem cells.
    Egashira T; Yuasa S; Suzuki T; Aizawa Y; Yamakawa H; Matsuhashi T; Ohno Y; Tohyama S; Okata S; Seki T; Kuroda Y; Yae K; Hashimoto H; Tanaka T; Hattori F; Sato T; Miyoshi S; Takatsuki S; Murata M; Kurokawa J; Furukawa T; Makita N; Aiba T; Shimizu W; Horie M; Kamiya K; Kodama I; Ogawa S; Fukuda K
    Cardiovasc Res; 2012 Sep; 95(4):419-29. PubMed ID: 22739119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterization of the human induced pluripotent stem cell (hiPSC) line NCUFi001-A from a patient carrying KCNQ1 G314S mutation.
    Lavra L; Magi F; Ulivieri A; Morgante A; Paulis M; Sala L; Pedrazzini M; Polisca P; Rocchetti M; Calò L; Sciacchitano S; Salehi LB
    Stem Cell Res; 2021 Jul; 54():102418. PubMed ID: 34130155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the CACNA1C-R518C Missense Mutation in the Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium Channel Perturbation.
    Estes SI; Ye D; Zhou W; Dotzler SM; Tester DJ; Bos JM; Kim CSJ; Ackerman MJ
    Circ Genom Precis Med; 2019 Aug; 12(8):e002534. PubMed ID: 31430211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1.
    Mura M; Ginevrino M; Zappatore R; Pisano F; Boni M; Castelletti S; Crotti L; Valente EM; Schwartz PJ; Gnecchi M
    Stem Cell Res; 2018 May; 29():170-173. PubMed ID: 29684900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.
    Lee HA; Hyun SA; Byun B; Chae JH; Kim KS
    PLoS One; 2018; 13(4):e0195577. PubMed ID: 29630634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue.
    Zhang M; D'Aniello C; Verkerk AO; Wrobel E; Frank S; Ward-van Oostwaard D; Piccini I; Freund C; Rao J; Seebohm G; Atsma DE; Schulze-Bahr E; Mummery CL; Greber B; Bellin M
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5383-92. PubMed ID: 25453094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.